IS IT TRUE JUNE 13, 2016

first_imgIS IT TRUE we just heard that all phones, radios and computers were down at Vanderburgh County Central Dispatch offices?  …we have just been told that the radios and phones are now back on line but the computers are not?   …our officials are working on restoring full services soon as possible? …we have no idea when full services will be restored at the Vanderburgh County Central Dispatch offices?IS IT TRUE all system at the Vanderburgh County Central Dispatch offices are back on line as of 11:55 am?   …the problem was reportedly caused by a power serge?IS IT TRUE that legal arguments will be heard this week in the suit by Planned Parenthood of Indiana and Kentucky against Indiana’s new abortion law?  …the US District Court Judge Tanya Walton Pratt will preside in the suit? …we wonder if the law is overturned, will Governor Pence spend more public money on an appeal?IS IT TRUE we thought that Deaconess Hospital officials announced last week that they are going to be less aggressive in the collecting of debts from past patients?   …last week one of our staff members received 7 phones calls from Deaconess Hospital collections department and a collections letter from their attorney located in Indy?  …the total sum of that our employee owed  Deaconess was a whooping $13?  …we won’t be surprised to hear that Deaconess Hospital officials next  move is to hire  “Dog The Bounty Hunter’ to collect this $13 debt?IS IT TRUE we are getting a kick out of Evansville DMD Director Kelley Coures stating that he is looking for the land bank projects that prove to be budget-conscious?  …if Mr. Coures statement is correct,  we wonder why he selected Evansville Brownfield Corp to be in charge of the awarding of future land bank projects?  …wasn’t  the Evansville Brownfields Corp in charge of past land bank projects that wasted many millions of dollars of our hard earned tax dollars?IS IT TRUE that Mayor Winnecke wants to construct a new pool at the present Lloyd pool area on the Northside?  …we wonder who is going to be responsible for the funding of this pool?  …the major users of the pool is Evansville/Vanderburgh County School Corporation? … the Evansville/Vanderburgh School Corporation should play a major role in paying for the construction of the new Lloyd pool? …shouldn’t they  also be responsible for the maintenance of this soon to be built pool?Todays “READERS POLL” question is:  Do you feel that the Evansville  Redevelopment Commission should provide the general public with annual audits, copies of there meeting agendas and approved minutes?IS IT TRUE we made a mistake in posting that a firm doing excavation work for DMD was locatedin Henderson County?  … the operator of the excavator firm was “from” Henderson but the firm contracted do the work for the city is from Evansville?  …we just took down the post because it was incorrect?Please take time and read our newest feature articles entitled “HOT JOBS” and “LOCAL SPORTS” posted in our sections.If you would like to advertise in the CCO please contact us City-County [email protected] 2015 City County Observer. All rights reserved. This material may not be published, broadcast, rewritten or redistributedFacebookTwitterCopy LinkEmailSharelast_img read more

Radiotherapy drug used for treating rare neuroendocrine cancers can be safe effective

first_imgMay 30 2018A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania. The study showed AZEDRA (ultratrace iobenguane I131) led to a significant reduction in the cardiovascular side effects that are associated with these cancers while also stopping tumor growth. The drug is designed to treat malignant, recurrent, or unresectable forms of the cancers – cases for which there are currently no approved non-surgical treatments. Progenics Pharmaceuticals, which manufactures AZEDRA, recently submitted the findings of this trial as part of an application for approval to the U.S. Food and Drug Administration. The study’s principal investigator Daniel A. Pryma, MD, an associate professor of Radiology and Radiation Oncology, and Chief of Nuclear Medicine and Clinical Molecular Imaging at Penn’s Perelman School of Medicine, will present the results at the American Society of Clinical Oncology 2018 Annual Meeting in Chicago as an oral abstract (Abstract #4005).”This represents real hope for patients, since as of right now, there are no anti-tumor therapies available for patients with these tumors who are not candidates for surgery,” Pryma said.Pheochromocytoma and paraganglioma are neuroendocrine tumors that form from the same type of tissue. Pheochromocytoma forms in the adrenal gland, while paraganglioma forms outside of the gland. There are an estimated 650 to 2600 new cases in the United States each year, with between 10 and 35 percent of cases metastatic or locally invasive at diagnosis. In addition, when the disease returns, it may not be resectable surgically. The five-year survival rate of unresectable cases can be as low as 12 percent.Related StoriesResearch sheds light on sun-induced DNA damage and repairLiving with advanced breast cancerStudy reveals link between inflammatory diet and colorectal cancer riskAZEDRA is a radiotherapy drug that attacks these tumors with a high, specifically-targeted dose. The FDA gave it an Orphan Drug designation, Fast Track status, and Breakthrough Therapy designation in the U.S.In the Penn-led trial, 68 patients received at least one therapeutic dose of AZEDRA. Twenty-five percent of patients who received at least one dose met the trial clinical benefit endpoint, and the number jumped to 32 percent in patients who received two doses. That clinical benefit was measured by a 50 percent or greater reduction in the amount of hypertensive medications these patients took lasting at least 6 months as high blood pressure and associated cardiovascular side effects are a major cause of harm from these cancers. Additionally, 92 percent of evaluable patients who received at least one dose achieved a partial response or stable disease.”Our data shows this therapy provides a dual benefit to patients by not only controlling the tumor, but also the debilitating symptoms caused by their excess hormone production,” Pryma said.The drug was generally well-tolerated, with the most common side effects being consistent with what a patient would experience with radiation such as decreased blood counts, fatigue, nausea, and dizziness. Source: read more